⌕
Kura Oncology · KURA · Nasdaq
Tenet 30 · Weak
Compare
$7.49+5.64%At closeTenet 30 · Weak
$7.49+0.40 (+5.64%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Kura Oncology (KURA) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

4 figures withheld by our checks. Each blank figure names its reason.

Business engineChoppy: revenue history is too short to read a growth trend, net margin −412.9%. Worth your attention in FY25: Share count (+32.1%) and Capex step-up ($6.6M). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲25.2%
67.5
FY21→FY25CAGR —
Net income ($M)▼60.2%
−278.7
FY21→FY25CAGR —
Free cash flow ($M)—
−70.7
capex stepped upCAGR —
Diluted EPS▼57.4%
−3.18
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+32.1%

66.4mn → 87.7mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex step-up
$6.6M

▲1306% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($K)67482.0Revenue−57.0COGS67425.0Gross profit−251074.0R&D−119982.0SG&A−303631.0Op income24965.0Tax & other−278666.0Net income

-413¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~3%FY21FY25

Net margin -412.9% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
79,314.067,482.053,883.00.00.00.0▲25.2%—
Cost of revenue
933.057.00.00.00.00.0——
Gross profit
78,381.067,425.0—A0.00.00.0——
Research & development
258,440.0251,074.0169,967.0115,235.092,812.084,721.0▲47.7%+31.2%
Selling, general & admin
132,692.0119,982.077,111.050,569.047,053.046,537.0▲55.6%+26.7%
Total operating expenses
391,132.0371,056.0247,078.0165,804.0139,865.0131,258.0▲50.2%+29.7%
Operating incomefeeds ROC rank
−312,751.0−303,631.0−193,195.0−165,804.0−139,865.0−131,258.0▼57.2%—
Other income, net
19,961.025,262.021,230.013,173.04,025.0792.0——
Pretax income
−292,790.0−278,369.0−171,965.0−152,631.0−135,840.0−130,466.0▼61.9%—
Income tax
84.0297.02,018.00.00.0—▼85.3%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−292,874.0−278,666.0−173,983.0−152,631.0−135,840.0−130,466.0▼60.2%—
Per share
Diluted EPSbuyback-sensitive
−3.30−3.18−2.02−2.08−2.03−1.97▼57.4%—
Diluted shares (mn)
89.8287.6886.1673.2366.9966.35▲1.8%+7.2%
Margins
Gross margin97th pct in Healthcare
98.8%99.9%—A—————
Operating margin
−394.3%−449.9%−358.5%———▼91.4pp—
Net margin5th pct in Healthcare
−369.3%−412.9%−322.9%———▼90.1pp—
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
FY15 – FY20 · 5 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-05 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Kura Oncology's revenue last fiscal year?

Kura Oncology reported revenue of $67.5M in fiscal 2025, up 25.2% from fiscal 2024.

What was Kura Oncology's net income?

Kura Oncology reported net income of −$278.7M in fiscal 2025, a net margin of −412.9%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.